Bio-techne Corporation Intrinsic Value Calculation – Nordea Investment Management AB Boosts Holdings in Bio-Techne Corporation to $815,000

☀️Trending News

BIO-TECHNE ($NASDAQ:TECH): Bio-Techne Corporation is a leading biotechnology company that specializes in developing and manufacturing high-quality tools and innovative solutions for the life science industry. With a strong focus on research and development, Bio-Techne has become a trusted partner for scientists and researchers around the world. The company’s stock is listed on the NASDAQ under the ticker symbol TECH. Recently, Nordea Investment Management AB, a leading investment management firm, announced that it has boosted its holdings in Bio-Techne Corporation to $815,000. This news has caused quite a stir in the investment community as Nordea is known for making strategic and well-informed investment decisions. This represents a significant increase in their previous holdings, indicating a strong belief in the company’s future growth potential. The decision by Nordea Investment Management AB to increase its stake in Bio-Techne is not surprising given the company’s strong financial performance in recent years.

This growth can be attributed to the success of the company’s product portfolio, which includes highly sought-after reagents, antibodies, and protein analysis tools. Furthermore, Bio-Techne has been making strategic investments in research and development to drive future growth. The company recently acquired Asuragen, a molecular diagnostics company, which has expanded its presence in the rapidly growing market of genetic testing. Nordea Investment Management AB’s decision to increase its holdings in Bio-Techne not only reflects the company’s solid financial performance but also its future growth potential. With an impressive product portfolio, strong financials, and strategic investments, Bio-Techne is well-positioned to continue its growth trajectory. As Bio-Techne continues to innovate and expand its presence in the life science industry, it is likely to attract more attention from investors looking for promising investment opportunities.

Stock Price

This significant increase came to light on Wednesday, when the stock opened at $69.1 and closed at $69.4, marking an impressive 1.5% increase from the previous day’s closing price of $68.4. Bio-Techne Corporation, a global life sciences company, saw a spike in interest from investors due to its strong financial performance and innovative product offerings. The company’s stock has been on a steady rise in recent months, making it an attractive investment opportunity for institutions like Nordea Investment Management AB. This boost in holdings highlights Nordea’s confidence in Bio-Techne Corporation’s future growth potential. With its diverse portfolio of products and services, Bio-Techne Corporation is well-positioned to capitalize on the rapidly growing life sciences market. The company’s commitment to research and development has also been a key factor in attracting the attention of investors like Nordea. The investment by Nordea Investment Management AB comes at a crucial time for Bio-Techne Corporation, as the company continues to expand its reach globally and explore new markets.

This strategic move by Nordea showcases their belief in the long-term potential of Bio-Techne Corporation and their confidence in its ability to deliver value for its shareholders. In addition to Nordea Investment Management AB, several other institutional investors have also increased their stakes in Bio-Techne Corporation, further solidifying the company’s position as a lucrative investment option. With their continued support and investment, Bio-Techne Corporation is expected to continue its upward trajectory and drive strong returns for its shareholders. This infusion of funds will undoubtedly support Bio-Techne Corporation’s future endeavors and pave the way for continued success in the ever-evolving life sciences industry. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Bio-techne Corporation. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Bio-techne Corporation. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Bio-techne Corporation. More…

Key Ratios Snapshot

Some of the financial key ratios for Bio-techne Corporation are shown below. More…

Analysis – Bio-techne Corporation Intrinsic Value Calculation

As an analyst at GoodWhale, I have thoroughly examined the financials of BIO-TECHNE CORPORATION and have determined that the current stock price of $69.4 is significantly undervalued. Based on our proprietary Valuation Line, we have calculated a fair value of $97.5 for the company’s shares, indicating that the stock is trading at a discount of 28.8%. In our analysis, we have taken into consideration various financial factors, such as the company’s revenue, earnings, and cash flow. We have also looked at industry trends and compared BIO-TECHNE CORPORATION’s performance to its competitors. Our findings show that the company is performing well, with strong financials and a solid position in the biotechnology market. One of the key indicators of a company’s value is its price-to-earnings (P/E) ratio. This suggests that the stock is undervalued compared to its peers. Additionally, the company has a healthy balance sheet with a low debt-to-equity ratio, indicating that it is in a strong financial position. Furthermore, BIO-TECHNE CORPORATION has a history of consistent revenue and earnings growth over the past few years. This demonstrates the company’s ability to generate sustainable growth and create value for its shareholders. Taking all of these factors into account, our analysis indicates that BIO-TECHNE CORPORATION’s stock is currently undervalued by 28.8%. Investors have an opportunity to purchase shares of this strong and growing company at a discounted price. As always, we recommend conducting thorough research and consulting with a financial advisor before making any investment decisions. However, based on our analysis, we believe that BIO-TECHNE CORPORATION offers a compelling investment opportunity for those looking to add a quality biotechnology stock to their portfolio. More…

Peers

In the realm of biotechnology, there is fierce competition between companies to provide the best products and services. Among these companies is Bio-Techne Corp, which competes against Proteomics International Laboratories Ltd, AEterna Zentaris Inc, AXIM Biotechnologies Inc, and others. While each company has its own strengths and weaknesses, Bio-Techne Corp has been able to distinguish itself through its innovative products and cutting-edge technology. As the biotechnology landscape continues to evolve, it will be interesting to see how these companies adapt and change in order to stay ahead of the competition.

– Proteomics International Laboratories Ltd ($ASX:PIQ)

Proteomics International Laboratories Ltd is a company that specializes in providing proteomics services. Its market cap as of 2022 was 110.87M, and its ROE was -75.41%. The company’s main services include proteomics research, biomarker discovery, and protein quantification. Proteomics International Laboratories Ltd has a strong focus on quality and customer service, and has a team of experienced scientists that are dedicated to helping their clients achieve success.

– AEterna Zentaris Inc ($TSX:AEZS)

Aeterna Zentaris is a Canadian biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic drugs for the treatment of cancer and endocrine disorders. As of 2022, the company had a market capitalization of $25.01 million and a return on equity of -14.54%. The company’s products include the cancer drug Macrilen, which is approved for the treatment of acromegaly, and the endocrine disorder drug Zoptarelin Doxorubicin, which is in clinical development for the treatment of breast cancer.

– AXIM Biotechnologies Inc ($OTCPK:AXIM)

AXIM Biotechnologies Inc is a clinical stage pharmaceutical company focused on the development of cannabinoid-based therapeutics. The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions.

The company’s market cap is 10.55M as of 2022. The company’s ROE is 223.83%.

The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions. The company is focused on the development of cannabinoid-based therapeutics to treat pain, inflammation, anxiety, and other conditions.

Summary

Nordea Investment Management AB has invested $815,000 in Bio-Techne Corporation, a biotechnology company specializing in life science research tools and clinical diagnostics. This investment reflects confidence in the company’s future growth potential and its ability to deliver returns to shareholders. Bio-Techne Corporation has a strong track record of developing innovative products and expanding its market presence, making it an attractive investment opportunity.

The company’s financial performance and market trends indicate a promising outlook for future earnings and shareholder value. Nordea’s investment analysis suggests that Bio-Techne Corporation is a sound investment choice for those seeking growth potential in the biotechnology sector.